Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The main objective of the clinical trial is to determine if modified FOLFIRINOX (mFFX)
alternated with biweekly Gemcitabine plus Nab-Paclitaxel (mGnabP) administered as a combined,
front-line therapy will result in longer time to treatment failure (TTF) compared to the
current standard of care with mFFX alone in treatment-naive patients with metastatic
pancreatic ductal adenocarcinoma (PDAC).